IRIDEX Corporation Stock News

IRIDEX Corporation (NASDAQ:IRIX ) Q2 2022 Earnings Conference Call August 15, 2022 5:00 PM ET Company Participants Leigh Salvo - Investor Relations David Bruce - Chief Executive Officer Fuad Ahmad - I

Iridex (IRIX) delivered earnings and revenue surprises of 12.50% and 1.22%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

MOUNTAIN VIEW, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal

IRIDEX Corporation (NASDAQ:IRIX ) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants David Bruce – Chief Executive Officer Hunter Cabi – Investor Relations Fuad Ahmad �

Iridex (IRIX) delivered earnings and revenue surprises of 6.25% and 0.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

MOUNTAIN VIEW, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal

New York, USA, March 16, 2022 (GLOBE NEWSWIRE) -- Ophthalmic Lasers Market Size is Anticipated to Grow at a CAGR of 6.11% by 2026, Assesses DelveInsight As per DelveInsight Analysis, the Ophthalmic Lasers market will grow due to the rising number of ophthalmic disorders and diseases, rise in the elderly population, wide acceptance of these devices, and advancements in new technologies along with other key factors, which are expected to increase the overall demand for Ophthalmic Lasers. According to the latest market research report published by DelveInsight " Ophthalmic Lasers Market Insight, Competitive Landscape & Forecast – 2026 ," the global Ophthalmic Lasers market is expected to witness significant growth owing to the increase in ophthalmic procedures like cataract surgeries, glaucoma surgeries, refractive surgeries. This report will provide an in-depth market understanding for Ophthalmic Lasers which will further benefit the key market competitors or stakeholders operating in the Ophthalmic Lasers market.

IRIDEX Corporation (IRIX) CEO Dave Bruce on Q4 2021 Results - Earnings Call Transcript

IRIDEX press release (IRIX): Q4 GAAP EPS of -$0.15.Revenue of $15.25M (+24.0% Y/Y).2022 Guidance: Iridex projects Cyclo G6 probe sales of 67,000 to 70,000 representing 15% to 20%…

Exceeds Prior Guidance with Record Fourth Quarter Revenue and 48% Full Year Revenue Growth Exceeds Prior Guidance with Record Fourth Quarter Revenue and 48% Full Year Revenue Growth

Iridex (IRIX) delivered earnings and revenue surprises of -36.36% and 0.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

MOUNTAIN VIEW, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in the upcoming 34 th Annual Roth Conference.

MOUNTAIN VIEW, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal

Iridex (IRIX) is trading +4.46% higher after-hour after issuing prelim results for Q4 and full year ended January 1, 2022.Q4 revenue is expected to be $15.1M to $15.3M (up around 24% Y/Y)